,trastuzumab deruxtecan
daiichi sankyo,astrazeneca
['trastuzumab', 'breast']
trastuzumab deruxtecan (t-dxd) for treating her2-low #breastcancer shows promise. #asco22 
The official account of Memorial Sloan Kettering Cancer Center, the Sloan Kettering Institute, and Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences